January 22, 2015

Kite Pharma Announces Expanded Agreement with Tel Aviv Sourasky Medical Center and Pioneering Researcher Professor Zelig Eshhar to Develop Novel Chimeric Antigen Receptor (CAR) Approaches for Cancer Immunotherapy

January 19, 2015

Kite Pharma Announces Presentations Highlighting Cancer Immunotherapy T Cell Manufacturing Process

January 12, 2015

Capricor Therapeutics Announces $10 Million Private Placement of Common Stock

January 12, 2015

Capricor Therapeutics Initiates the DYNAMIC Clinical Trial for the Treatment of Advanced Heart Failure

January 9, 2015

Kite Pharma Expands Senior Management Team With Appointment of Claudine Prowse, Ph.D., as SVP, Corporate Communications and Investor Relations

January 8, 2015

Kite Pharma Announces Addition of Scott N. Bernstein as Vice President of Intellectual Property Law

January 8, 2015

Arno Therapeutics to Present at 11th Annual Noble Equity Conference

January 7, 2015

Kite Pharma Announces Exclusive License With the National Institutes of Health for T Cell Receptor (TCR)-Based Products to Treat HPV-Associated Cancers

January 7, 2015

Kite Pharma to Present at the 33rd Annual J.P. Morgan Healthcare Conference

January 6, 2015

Kite Pharma Granted Orphan Drug Designation in the European Union for KTE-C19, Kite’s Lead Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy

January 5, 2015

Amgen and Kite Pharma Announce Strategic Cancer Immunotherapy Collaboration to Advance the Application of Novel Chimeric Antigen Receptor (CAR) T Cell Therapies

December 30, 2014

Kite Pharma Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares

December 22, 2014

Kite Pharma Submits Investigational New Drug Application for Phase 1/2 Trial of KTE-C19, Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, for the Treatment of Refractory Aggressive Non-Hodgkin Lymphoma

December 16, 2014

Kite Pharma Added to the NASDAQ Biotechnology Index

December 10, 2014

Kite Pharma Announces Pricing of Follow-On Offering

December 10, 2014

Arno Therapeutics Doses First Patient in Expansion Stage of Modified Phase I/II Trial Evaluating Onapristone in Progesterone Receptor Positive Tumors

December 9, 2014

Arno Therapeutics to Present Data Further Validating Diagnostic Development of CDx for Onapristone at San Antonio Breast Cancer Symposium 2014

December 4, 2014

Arno Therapeutics Appoints Alexander Zukiwski, M.D. to Board of Directors –

December 2, 2014

Capricor Therapeutics Announces Linda Marban, Ph.D. Will Present a Company Overview and Serve as an Expert Panelist at Piper Jaffray’s 26th Annual Healthcare Conference

November 26, 2014

Kite Pharma Files Registration Statement for Proposed Follow-On Offering

November 24, 2014

Arno Therapeutics to Present at LD Micro Conference 2014

November 18, 2014

Kite Pharma Announces Presentations at the Upcoming 56th American Society of Hematology Annual Meeting

November 18, 2014

Capricor Therapeutics Announces Favorable ALLSTAR Phase I Safety Results

November 18, 2014

Capricor Therapeutics Announces Positive Pre-Clinical Data for Cardiosphere-Derived Cells (CDCs) on Duchenne Muscular Dystrophy Cardiomyopathy

November 17, 2014

Kite Pharma Receives Positive Opinion for Orphan Drug Designation in the European Union for KTE-C19, Kite’s Lead Investigational Cancer Immunotherapy